Conditions: Parkinson's Disease (PD)
Keywords: Parkinson's disease (PD) Opicapone Bia 9-1067
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 16
Healthy volunteers: yes

Brief summary:
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of immediate-release levodopa/benserazide 100/25 mg (Prolopa® 100-25)

Detailed description:

Arms:
arm 1: Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo

Every period with concomitant single oral administration of Prolopa® 100-25 arm 2: Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg

Every period with concomitant single oral administration of Prolopa® 100-25 arm 3: Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg

Every period with concomitant single oral administration of Prolopa® 100-25 arm 4: Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg

Every period with concomitant single oral administration of Prolopa® 100-25

Interventions: intervention 1: BIA 9-1067 intervention 2: Placebo intervention 3: Prolopa®
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: levodopa/benserazide 100/25 mg

Protocol document: